FDA maps a broader route for nonprescription drugs
FDA has laid out a formal stakeholder engagement plan aimed at expanding access to nonprescription drug products through the drug application process, including prescription-to-nonprescription switches. The agency is tying that effort to a simple public health premise: when an appropriate medicine can be used safely without a licensed clinician at the point of purchase, more patients can treat common conditions earlier and outside the traditional prescription channel.
The plan is not a one-step policy memo. It is a staged regulatory roadmap built around public input, meetings, a future pilot program, and draft guidance for industry. Each of those pieces is meant to sharpen the same question: which approved prescription medicines can be moved into the nonprescription setting without compromising safety, effectiveness, or appropriate use?
Consumers already buy nonprescription medicines in pharmacies, supermarkets, and online. FDA’s position is that widening access to suitable products can support self-care and improve public health, but only when the evidence shows people can select and use those drugs appropriately on their own.
Public input, anaphylaxis, and the practical limits of self-care
The first major step came on December 2, 2025, when FDA issued a request for information titled “Increasing Access to Nonprescription Drugs.” The agency asked interested parties and the public to identify diseases or conditions that have not traditionally been treated with nonprescription products but might be managed safely and effectively without supervision from a licensed healthcare practitioner. That framing signals a deliberate shift away from treating OTC access as a static category. Instead, FDA is asking where the boundary between prescription and nonprescription care could reasonably move.
A few weeks later, on December 16, 2025, FDA held a public meeting focused on an especially consequential example: anaphylaxis and access to epinephrine. The meeting examined whether expanding epinephrine availability, including in the nonprescription setting, could improve outcomes in a condition where delay can be fatal. Epinephrine acts quickly on vascular tone and bronchial constriction, and its value depends heavily on speed of administration. A drug that is already pharmacologically well suited to urgent rescue loses much of its benefit if access barriers keep it out of reach when symptoms begin.
This is where the regulatory discussion becomes clinically real.
The agency is asking which drugs belong in the hands of consumers
FDA’s April 23, 2026 public meeting broadened the conversation beyond a single product class. The meeting brought together drug developers, health care providers, patient and consumer representatives, and other stakeholders to discuss practical issues affecting access and the public health consequences of broader availability. Participants examined which drugs are best suited for prescription-to-nonprescription switches, what evidence is needed to prove safety and effectiveness in the nonprescription setting, and how innovation might support access through an additional condition for nonprescription use, or ACNU.
ACNU matters because it offers a middle path between unrestricted retail access and conventional prescription control. In practice, it can preserve safeguards while allowing a medication to move closer to the consumer. For a drug with clear benefit but meaningful use complexity, that structure may reduce misuse without keeping the treatment locked behind a prescription barrier. FDA’s inclusion of ACNU in the plan suggests the agency sees access design as more than a binary choice between over-the-counter and prescription-only status.
The agency also reopened the public docket tied to the December 2025 request for information, extending the chance for outside comments on the topics discussed at the April meeting and on broader access questions. That move keeps the policy process open while the agency continues to refine its framework.
A pilot program and guidance signal a more structured review process
In calendar year 2026, FDA intends to announce a pilot program to support development of nonprescription drug products, including Rx-to-OTC switches. The stated purpose is efficiency, but the deeper implication is process discipline. Early and structured discussions between sponsors and FDA can surface design problems, labeling issues, consumer comprehension concerns, and evidence gaps before a development program becomes too rigid to adapt.
For sponsors, that kind of early exchange can determine whether a candidate product is realistic for nonprescription use. For regulators, it offers a way to compare products against a common set of expectations before applications are fully assembled. In nonprescription development, the barrier is rarely chemistry alone. The larger issue is whether a person without clinical training can identify the right product, use it correctly, recognize when it is inappropriate, and know when to seek more urgent care.
FDA also plans to issue guidance for industry on developing nonprescription drugs, including considerations for identifying candidate products. Draft guidance will go out for public comment before finalization. That sequencing gives stakeholders a formal opportunity to weigh in on the standards that may govern future switches and new nonprescription development programs.
Statutory pressure is driving the timeline
The agency’s obligation comes from Section 505(b)(7) of the Federal Food, Drug, and Cosmetic Act, added by the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026, enacted November 12, 2025. Under that provision, FDA must develop and publicly share a plan to engage stakeholders on the steps and factors application holders and others should consider when identifying approved prescription products that may be promising candidates for an Rx-to-nonprescription switch.
Two regulatory routes remain available for nonprescription products in the United States. One is the OTC drug review process under Section 505G of the FD&C Act. The other is the application process under Section 505, under which FDA can approve a product as either prescription or nonprescription. The distinction matters because the underlying evidence pathway changes how a drug reaches the market, even when the active ingredient is the same.
The larger policy question is not whether all prescription drugs should become more accessible. It is which medicines can safely move into consumer hands, which safeguards are necessary, and what evidence should persuade FDA that a switch will improve care rather than simply shift risk from the clinic to the checkout aisle. The current plan does not answer that for any individual product, and it does not set a timetable for specific approvals. It does, however, establish the framework FDA will use as those decisions arrive, and that framework will likely shape every future nonprescription switch reviewed under the new statute.